Fringe movements are using games and other online platforms to draw growing numbers of children to their causes, new data and dozens of interviews show.
If you’ve been watching the JavaScript landscape for a while, you’ve likely noticed the trend toward simplicity in web application development. An aspect of this trend is leveraging HTML, REST, and ...
People are already turning to AI to answer questions, compare products, and make decisions in seconds. That shift exposes a fundamental problem: the web’s underlying structure was never built for ...
Your favorite latte at the local coffee shop could soon cost $5, $5.10 or $5.25—depending on how you pay. A settlement between Visa, Mastercard and U.S. merchants announced this week could usher in a ...
Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...
LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) ...
On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses increased 34.6% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results